Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?

Group 1 - Arbutus Biopharma (ABUS) has gained approximately 60.8% year-to-date, outperforming the Medical sector average gain of 9.7% [2][3] - The Zacks Consensus Estimate for ABUS' full-year earnings has increased by 2.6% in the past quarter, indicating stronger analyst sentiment and an improving earnings outlook [2] - Arbutus Biopharma is ranked 6 in the Zacks Sector Rank and has a Zacks Rank of 2 (Buy), suggesting a favorable investment outlook [1][2] Group 2 - Arbutus Biopharma is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 0.3% year-to-date, highlighting ABUS's relative strength in this sector [3] - Astrazeneca (AZN), another outperforming stock in the Medical sector, has gained 14.1% year-to-date and has a Zacks Rank of 2 (Buy) [2][3] - The Large Cap Pharmaceuticals industry, to which Astrazeneca belongs, has performed well with a year-to-date increase of 22.7% [3]